NCT00216840

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis

Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,350 (planned)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate whether once daily topical treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle and calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis. The primary response criterion is the number of patients with absence of disease and very mild disease after 8 weeks of treatment.

Conditions

• Psoriasis of Scalp

Interventions

Type	Name	Description
DRUG	Calcipotriol plus betamethasone dipropionate (LEO80185 gel)

Timeline

• Start date: 2004-12-01
• Completion: 2005-09-01
• First posted: 2005-09-22
• Last updated: 2025-02-24

Locations

7 sites across 7 countries: Belgium, Canada, Finland, France, Germany, Netherlands, United Kingdom